SGP - Spyglass Pharma, Inc.

Insider Purchase by Behbahani Ali (Dir, 10%)

1 Month
After Trade
Before Trade

Loading data...

Trade Summary

1 week ago, Behbahani Ali, serving as Dir, 10% owner at Spyglass Pharma, Inc. (SGP), purchased 937,500 shares at $16.00 per share, for a total transaction value of $15,000,000.00. Following this transaction, Behbahani Ali now holds 7,392,301 shares of SGP.

This purchase represents a 15.00% increase in Behbahani Ali's stake in the company. This is considered a high-conviction trade given the significant change in ownership.

The trade was executed on Monday, February 9, 2026 and publicly disclosed via SEC Form 4 filing on Wednesday, February 11, 2026, 2 days after the trade was made.

Behbahani Ali

Dir, 10%

Ali Behbahani, M.D., M.B.A. is a Partner and Co-Head of the Healthcare team at New Enterprise Associates (NEA), a venture capital firm, where he has worked since 2007, specializing in biopharmaceuticals, medical devices, and related sectors.[[2]](https://www.spyglasspharma.com/about-us/)[[5]](https://crisprtx.com/about-us/leadership/dr-ali-behbahani)[[6]](https://www.nea.com/team/ali-behbahani-md) He serves as an Independent Director and 10% Owner of SpyGlass Pharma, Inc. (SGP), with recent insider transactions including the conversion of NEA funds' preferred stock to common stock and the acquisition of 937,500 shares for $15 million around the company's IPO in February 2026.[[1]](https://www.stocktitan.net/sec-filings/SGP/form-4-spy-glass-pharma-inc-insider-trading-activity-37495dc0e8a5.html)[[2]](https://www.spyglasspharma.com/about-us/)[[3]](https://www.stocktitan.net/sec-filings/SGP/form-4-spy-glass-pharma-inc-insider-trading-activity-1b4836dafe8b.html)[[9]](https://www.tipranks.com/news/insider-trading/spyglass-pharma-insiders-make-a-massive-high-stakes-bet-on-the-companys-future-insider-trading) Behbahani holds an MD from the University of Pennsylvania School of Medicine, an MBA from The Wharton School, and bachelor’s degrees in biomedical engineering, electrical engineering, and chemistry from Duke University.[[6]](https://www.nea.com/team/ali-behbahani-md) His career highlights include prior roles at The Medicines Company, Morgan Stanley, and Lehman Brothers, research at the National Institutes of Health and Duke, and board seats at numerous biotech firms such as CRISPR Therapeutics (since 2015), Nkarta (Chairman since 2019), Arcellx, Black Diamond Therapeutics, Monte Rosa Therapeutics, and Korro Bio.[[5]](https://crisprtx.com/about-us/leadership/dr-ali-behbahani)[[6]](https://www.nea.com/team/ali-behbahani-md)[[7]](https://tunetx.com/employee/ali-behbahani/)[[8]](https://www.korrobio.com/team-member/ali-behbahani-m-d/)

View full insider profile →

Trade Price

$16.00

Quantity

937,500

Total Value

$15,000,000.00

Shares Owned

7,392,301

Trade Date

Monday, February 9, 2026

13 days ago

SEC Filing Date

Wednesday, February 11, 2026

Filed 2 days after trade

About Spyglass Pharma, Inc.

Company Overview

No company information available
View news mentioning SGP

💬 Want Deeper Insight?

Use our AI assistant to ask questions about this trade, the insider, or the company.

Chat with AI

Share this trade

https://insidersignal.ai/trade/3898252

🚀 Track Insider Trades in Real-Time

Create a free account to access our full database of insider trades, AI-powered analysis, price alerts, and discover what corporate executives are buying and selling.

✓ Free forever plan available  •  ✓ No credit card required  •  ✓ Cancel anytime